Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 27 for your search:
Cancer Type/Condition:
Ewing sarcoma/PNET
Stage/Subtype:
metastatic Ewing sarcoma/PNET
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase III Randomized Study of Standard Induction Chemotherapy Comprising Vincristine, Dactinomycin, Ifosfamide, and Etoposide Followed By Consolidation Chemotherapy Comprising Vincristine, Dactinomycin, and Ifosfamide Versus High-Dose Busulfan and Melphalan Followed By Autologous Peripheral Blood Stem Cell Support With or Without Radiotherapy and/or Surgery in Patients With Tumor of the Ewing's Family
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 50
Sponsor:
NCI, Other
Protocol IDs:
EURO-EWING-INTERGROUP-EE99
, EBMT-INTERGROUP-EE99, EORTC-62981, GPOH-AUSTRIA-INTERGROUP-EE99, GPOH-GERMANY-INTERGROUP-EE99, SFOP-INTERGROUP-EE99, SWS-SAKK-INTERGROUP-EE99, CCLG-INTERGROUP-EE99, COG-AEWS0331, NCT00020566, AEWS0331
2.
Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Eval. of the Efficacy of Ridaforolimus)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
13 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
AP23573-07-302
, NCT00538239
3.
Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
BMT 0499 Solid
, NCT00179816
4.
Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
10 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
A4021020
, NCT00560235
5.
Phase I/II Study of Dasatinib in Combination With Ifosfamide, Carboplatin, and Etoposide Phosphate in Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 25
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
CHNMC-07053
, 07053, CA180 121, NCT00788125
6.
Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
19 months to 35 years
Sponsor:
NCI
Protocol IDs:
070206
, 07-C-0206, NCT00923351
7.
Phase II Pilot Study of Induction Chemotherapy Followed By Allogeneic/Syngeneic Peripheral Blood Stem Cell Transplantation in Patients With High-Risk, Recurrent Pediatric Sarcoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
4 to 35
Sponsor:
NCI
Protocol IDs:
NCI-02-C-0259
, NCT00047372
8.
Phase II Study of Umbilical Cord Blood as a Source of Hematopoietic Stem Cells for Transplantation in Children With Malignant or Non-Malignant Diseases
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
PSCI-2003-232
, NCT00084695
9.
Phase II Study of Intrathecal Iodine I 131 Monoclonal Antibody 3F8 in Patients With GD2-Expressing Central Nervous System or Leptomeningeal Neoplasms
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Any age
Sponsor:
Other
Protocol IDs:
MSKCC-05122
, NCT00445965
10.
Phase II Pilot Study of Irradiated Allogeneic Related Donor Lymphocyte Infusion in Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
CINJ-3330
, NCT00161187
11.
Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
30 and under
Sponsor:
NCI, Other
Protocol IDs:
05-326
, NCT00592293
12.
A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
12 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CP13-0707
, EudraCT Number: 2007-006719-21, NCT00668148
13.
A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
16 and over
Sponsor:
Other
Protocol IDs:
UMCC 2008.049
, NCT00743509
14.
Phase I Study of Interleukin-12 and Interleukin-2 in Patients With Refractory or Advanced Solid Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-00-C-0121
, NCI-41, 41, NCT00020163
15.
Phase I Study of Yttrium Y 90-DOTA-tyr3-Octreotide in Children With Advanced or Refractory Somatostatin Receptor-Positive Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
2 to 25
Sponsor:
NCI
Protocol IDs:
UIHC-200008086
, NCI-V02-1710, NCT00049023, 200008086
16.
Phase I Study of Intrathecal Iodine I 131 Monoclonal Antibody 8H9 in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
MSKCC-03133
, NCT00089245
17.
Gene Therapy for Pleural Malignancies
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
803776
, UPCC 03505, NCT00299962
18.
Phase I Study of Lexatumumab With or Without Recombinant Interferon Gamma in Pediatric Patients With Relapsed or Refractory Solid Tumors or Lymphoma
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 30
Sponsor:
NCI
Protocol IDs:
NCI-07-C-0040
, NCI-P6981, NCT00428272
19.
Phase I Study of Trabectedin in Pediatric Patients With Relapsed or Refractory Solid Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
4 to 16
Sponsor:
NCI
Protocol IDs:
NCI-07-C-0054
, NCT00437047
20.
Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Patients With Advanced or Refractory Solid Tumors
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
2 to 21
Sponsor:
NCI
Protocol IDs:
NCI-08-C-0007
, 08-C-0007, NCI-P6068, 7458, NCT00556881
21.
Phase I Study of Total Marrow Irradiation With Helical Tomotherapy Image-Guided Intensity-Modulated Radiotherapy Followed by Alkylator-Intense Conditioning Comprising Busulfan, Melphalan, and Thiotepa and Autologous CD34+ Hematopoietic Progenitor Cell Transplantation in Patients With High-Risk or Relapsed Solid Tumors
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Diagnostic, Treatment
Status:
Active
Age:
70 and under
Sponsor:
NCI
Protocol IDs:
UMN-2005LS023
, UMN-2005LS023, UMN-MT2004-30, NCT00623077
22.
Phase I Study of Anti-IGF-1R Recombinant Monoclonal Antibody IMC-A12 in Combination With Temsirolimus in Patients With Locally Advanced or Metastatic Cancer
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
MDA-2007-0595
, 2007-0595, 8109, NCT00678223
23.
RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
09-091
, NCT00927966
24.
Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
CDR0000449681
, CASE-CCF-7509, CASE-CCF-1062, NCT00311558
25.
Pilot Study of Cyclophosphamide and Cryoablation in Patients With Advanced or Metastatic Epithelial Solid Cancer
Phase:
No phase specified
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Over 18
Sponsor:
NCI
Protocol IDs:
JHOC-J0685
, NA_00003073, J0685, NCT00499733
Select All on Page
1
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
